In secondary endpoints, 64.6% of participants using Zepbound saw 15% weight loss compared with 40.1% on Wegovy. And Zepbound participants saw their waists reduced by an average 7.2 in (18.4 cm), ...

GLP-1 RA helped resolution of steatohepatitis without worsening fibrosis and reduced liver fibrosis without worsening steatohepatitis.

Hims & Hers delivered impressive Q1 2025 results, with 111% y/y revenue growth and 38% y/y subscriber growth. Check out why I ...

Findings showed a 13.6% reduction in body weight in the semaglutide 25mg group compared with a 2.2% reduction in the placebo group.

People taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy in ...

At 72 weeks, participants using Zepbound saw an average weight-loss reduction of 20.2% versus 13.7% with Novo Nordisk's own treatment, Eli Lilly said of the results presented at the European Congress ...

Di first head-to-head trial of two ogbonge weight-loss drugs show say Mounjaro dey more effective pass im rival Wegovy. Both ...

The first head-to-head trial of two blockbuster weight-loss drugs has shown Mounjaro is more effective than rival Wegovy.

The first head-to-head trial of obesity drugs reveals a clear winner for effective weight loss. But how does it work, and what are the long-term effects? Anna Magee reports ...

Q. I took Wegovy for a few months last fall until I was unable to find a pharmacy that could fill my prescription. They were ...

Q2 2025 Results Conference Call May 8, 2025 8:00 AM ETCompany ParticipantsSam Fisch - Executive Director, Investor Relations ...

Q. I took Wegovy for a few months last fall until I was unable to find a pharmacy that could fill my prescription. They were all out of stock.